Nitrogen-Containing Heterocyclic Compounds for Muscarinic Receptor Treatment
Summary
USPTO published patent application US20260109700A1 on April 23, 2026, filed October 27, 2023 as Application No. 19121822, disclosing nitrogen-containing heterocyclic compounds represented by formula I and their pharmaceutical salts. The inventors—Deheng Chen, Haifei Jia, Huaqiong Shen, and Lele Zhao—claim the compounds function as positive allosteric modulators of muscarinic receptors for treatment of M receptor-mediated diseases.
“The compounds of the present invention can be used as positive allosteric modulators of muscarinic receptors.”
About this source
USPTO classification C07D covers heterocyclic organic compounds: the chemical core of most small-molecule drugs, including kinase inhibitors, GLP-1 receptor agonists, antibiotics, antivirals, and CNS therapies. Every newly published application in C07D lands in this feed, around 160 a month. Applications publish 18 months after filing, so this feed reveals what medicinal chemistry groups at Pfizer, Novartis, Roche, Shionogi, and others were synthesizing in the prior year and a half. Watch this if you run a medicinal chemistry program, file patent clearance for new drug candidates, scout competitor pipelines before clinical readouts, or track heterocyclic innovation across therapeutic areas.
What changed
USPTO published patent application US20260109700A1 disclosing nitrogen-containing heterocyclic compounds and pharmaceutical salts for muscarinic receptor modulation. The application claims compounds of formula I as positive allosteric modulators of M receptors suitable for treating M receptor-mediated diseases.
Affected parties include pharmaceutical researchers developing muscarinic receptor-targeted therapies. Patent applications do not create immediate compliance obligations but establish priority rights and public disclosure of the claimed invention, signaling potential future licensing opportunities or competitive filings in this therapeutic area.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR, AND THE USE THEREOF
Application US20260109700A1 Kind: A1 Apr 23, 2026
Inventors
Deheng CHEN, Haifei JIA, Huaqiong SHEN, Lele ZHAO
Abstract
Disclosed in the present invention are nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof, a preparation method therefor, and the use thereof. Provided in the present invention are compounds represented by formula I or pharmaceutically acceptable salts thereof. The compounds of the present invention can be used as positive allosteric modulators of muscarinic receptors. The compounds of the present invention can be used for treatment of M receptor-mediated (or M receptor-related) diseases.
CPC Classifications
C07D 487/04 A61K 31/5025 A61K 31/506
Filing Date
2023-10-27
Application No.
19121822
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.